GELF17 |
All of the following: |
Maximum diameter of disease < 7 cm |
Fewer than 3 nodal sites |
No systemic symptoms |
Spleen < 16 cm on CT |
No significant effusions |
No risk of local compressive symptoms |
No circulating lymphoma cells |
No marrow compromise (Hb < 10 g/dL, WBC count < 1.5 × 109/L, platelet count < 100 × 109/L) |
BNLI18 |
None of the following: |
B symptoms or pruritus |
Rapid generalized disease progression |
Marrow compromise (Hb ≤ 10 g/dL, WBC count < 3.0 × 109/L, or platelet count < 100 × 109/L) |
Life-threatening organ involvement |
Renal infiltration |
Bone lesions |
GELF17 |
All of the following: |
Maximum diameter of disease < 7 cm |
Fewer than 3 nodal sites |
No systemic symptoms |
Spleen < 16 cm on CT |
No significant effusions |
No risk of local compressive symptoms |
No circulating lymphoma cells |
No marrow compromise (Hb < 10 g/dL, WBC count < 1.5 × 109/L, platelet count < 100 × 109/L) |
BNLI18 |
None of the following: |
B symptoms or pruritus |
Rapid generalized disease progression |
Marrow compromise (Hb ≤ 10 g/dL, WBC count < 3.0 × 109/L, or platelet count < 100 × 109/L) |
Life-threatening organ involvement |
Renal infiltration |
Bone lesions |
To convert Hb from grams per deciliter to grams per liter, multiply grams per deciliter by 10.
GELF indicates Groupe pour l'Etude de Lymphome Folliculaire; Hb, hemoglobin level; WBC, white blood cell; BNLI, British National Lymphoma Investigation.